Using Misoprostol to Prevent Cervical Cancer
Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial
This study is testing if the medication Misoprostol can help prevent cervical cancer in women who are being screened for the disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 420 (estimated) |
| Ages | 25 Years and up |
| Sex | Female |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Yaoundé, Center Region) |
| Trial ID | NCT06669533 on ClinicalTrials.gov |
What this trial studies
This clinical trial involves a double-blind randomized controlled approach with 420 non-pregnant women who are undergoing cervical cancer screening using visual inspection with acetic acid. Participants diagnosed with Type 3 transformation zone (TZ) will be randomly assigned to receive either Misoprostol or a placebo. The goal is to evaluate the effectiveness of Misoprostol in optimizing the prevention of cervical cancer in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are non-pregnant women aged 25 years or older with a confirmed diagnosis of Type 3 transformation zone.
Not a fit: Patients with Type 1 or 2 transformation zones, those who are currently pregnant, or individuals with a history of hysterectomy or active cervicitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance cervical cancer prevention strategies, potentially reducing the incidence of the disease.
How similar studies have performed: Other studies have explored the use of Misoprostol in cervical cancer prevention, indicating potential for success, though this specific approach may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Type 3 TZ confirmed on exam prior to randomization * Age 25 years or older Exclusion Criteria: * With Type 1 or 2 TZ prior to randomization * Currently pregnant * History of hysterectomy * Any cancerous lesions * Active cervicitis
Where this trial is running
Yaoundé, Center Region
- Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé — Yaoundé, Center Region, Cameroon (Recruiting)
Study contacts
- Principal investigator: Warner K Huh, MD — University of Alabama at Birmingham
- Study coordinator: Warner K Huh, MD
- Email: whuh@uabmc.edu
- Phone: 2059341555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.